Alphyn Biologics is a life science company dedicated to developing proprietary plant-based drug therapies for treating severe skin diseases, including infections caused by drug-resistant MRSA bacteria. Utilizing their Multi-Target Therapeutic (MTT) technology platform, Alphyn aims to address significant unmet medical needs in dermatology. Their market focus includes conditions like atopic dermatitis, leveraging innovative plant-derived solutions to offer effective treatments.
Alphyn Biologics has achieved significant milestones, including positive results from the second cohort of their Phase 2a clinical trial in atopic dermatitis. They have also presented interim results from their first human phase trial of Zabalafin (AB-101a) at the Masters of Pediatric Dermatology Symposium. These advancements underscore Alphyn's commitment to pioneering new therapies in dermatology, positioning them as a key player in the field of skin disease treatment.
